Wellington Management Group LLP Sells 24,967 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Wellington Management Group LLP lowered its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 4.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 496,227 shares of the biotechnology company’s stock after selling 24,967 shares during the quarter. Wellington Management Group LLP’s holdings in Heron Therapeutics were worth $987,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in HRTX. Bank of New York Mellon Corp increased its holdings in Heron Therapeutics by 33.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 449,212 shares of the biotechnology company’s stock worth $1,572,000 after acquiring an additional 113,655 shares in the last quarter. Legato Capital Management LLC purchased a new stake in shares of Heron Therapeutics in the second quarter worth $837,000. HB Wealth Management LLC purchased a new stake in shares of Heron Therapeutics in the second quarter worth $35,000. Panagora Asset Management Inc. raised its position in shares of Heron Therapeutics by 49.8% during the 2nd quarter. Panagora Asset Management Inc. now owns 562,228 shares of the biotechnology company’s stock valued at $1,968,000 after purchasing an additional 186,802 shares during the period. Finally, nVerses Capital LLC purchased a new position in shares of Heron Therapeutics during the 2nd quarter valued at $27,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Stock Performance

Shares of NASDAQ HRTX opened at $1.53 on Friday. The firm’s fifty day moving average is $1.56 and its two-hundred day moving average is $2.23. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.93. The company has a market cap of $232.71 million, a P/E ratio of -8.50 and a beta of 1.67.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The firm had revenue of $32.81 million during the quarter, compared to analysts’ expectations of $36.40 million. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. As a group, analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Wednesday, December 4th. StockNews.com downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.